Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Cash from Operations (2017 - 2025)

Protagonist Therapeutics' Cash from Operations history spans 9 years, with the latest figure at 36975000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations fell 26.72% year-over-year to 36975000.0; the TTM value through Dec 2025 reached 57671000.0, down 68.68%, while the annual FY2025 figure was 57671000.0, 68.68% down from the prior year.
  • Cash from Operations for Q4 2025 was 36975000.0 at Protagonist Therapeutics, down from 1937000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 268622000.0 in Q2 2024 and bottomed at 37666000.0 in Q1 2022.
  • The 5-year median for Cash from Operations is 27184000.0 (2021), against an average of 2220750.0.
  • The largest YoY upside for Cash from Operations was 1123.79% in 2024 against a maximum downside of 272.04% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 26939000.0 in 2021, then decreased by 17.43% to 31635000.0 in 2022, then skyrocketed by 153.61% to 16960000.0 in 2023, then tumbled by 272.04% to 29178000.0 in 2024, then decreased by 26.72% to 36975000.0 in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Cash from Operations are 36975000.0 (Q4 2025), 1937000.0 (Q3 2025), and 28780000.0 (Q2 2025).